AFP and hepatocellular carcinoma: We previously reported a specific therapeutic effect of anti-AFP and anti-CEA mouse monoclonal antibody (MAb)-conjugated liposomes containing doxorubicin (DXR) for an AFP-producing hepatoma (Konno et al, 1987) and a CEA-positive tumour (Uyama et al, 1994), respectively.